Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$124.73 USD

124.73
908,797

+2.45 (2.00%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $124.80 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ILMN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Illumina, Inc. [ILMN]

Reports for Purchase

Showing records 341 - 360 ( 360 total )

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 341

03/20/2011

Daily Note

Pages: 4

Buyers on Recent Selloff & Closure of Note Offering; Fears of Large Dilutive Deal Unrealistic

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 342

03/15/2011

Daily Note

Pages: 4

Announces $800 MM Convertible Note Issue

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 343

02/16/2011

Company Report

Pages: 7

PACB 4Q10 Highlights; Timelines, Specs on Track; 150k Upgrade Begun; Co. Indicating Readlength Headroom

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 344

02/09/2011

Company Report

Pages: 11

No 4Q10 Surprises; Sequencing Business Dominating; GMs Tolerable & OpEx Fine; Reaffirming OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 345

02/09/2011

Company Report

Pages: 5

4Q10 Results Review: Solid Quarter; But Closing In On Our Price Target; Downgrade to Hold

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 346

02/04/2011

Company Report

Pages: 6

4Q10 Preview; Juicy Announcements Unlikely; Excited by HiSeq Consumables & MiSeq; Admitting Defeat with Prior Multiple;

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 347

01/12/2011

Company Report

Pages: 8

Repeats Best-in-Show at JPM; Positive 4Q10 Rev Preannouncement

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 348

01/12/2011

Company Report

Pages: 5

Releases 4Q10 Results and Preliminary 2011 Guidance; Updates Pipeline Progress.

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 349

12/09/2010

Company Report

Pages: 5

Broadening Applications and Customer Base Bode Well; Raising Price Target to $75.

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 350

10/27/2010

Company Report

Pages: 9

Strong 3Q10 Across the Board; Acceleration in Genotyping Surprises; Sequencing Solid as Ever; Eclipsing 2010 Guidance

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 351

10/27/2010

Company Report

Pages: 5

Strong Upgrade Cycle and Broadening Customer Base; Increasing Price Target to $60.

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 352

10/25/2010

Company Report

Pages: 6

3Q10 Financial Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 353

10/25/2010

Daily Note

Pages: 6

3Q10 Earnings Preview: Likely Steady As She Goes.

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 354

10/22/2010

Company Report

Pages: 8

Pacific Biosciences Cost Per Genome Sensitivity Analysis; Accuracy and Actual Cost Per Genome Unclear from IPO Roadshow Chatter

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 355

10/13/2010

Company Report

Pages: 23

Assuming Coverage of ILMN with an OUTPERFORM Rating and $60 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 75.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 356

07/28/2010

Company Report

Pages: 5

Strong Quarter and Robust Guidance.

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 357

06/30/2010

Company Report

Pages: 4

New Products Pick-Up Bode Well; Reiterate Buy

Provider: AURIGA USA

Analyst: MEHRA R

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 358

04/29/2010

Company Report

Pages: 5

Robust Quarter; Reiterating Buy

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 359

02/05/2010

Company Report

Pages: 5

Reported Q4 and Guidence for 2010 in line with Preannounced Numbers

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 360

01/25/2010

Company Report

Pages: 5

IT''S ALL ABOUT GENOMES ;RAISING PRICE TARGET TO $49.

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party